Thus, nebivolol is, with regard to hemodynamic and metabolic properties, similar to carvedilol, although the two act slightly differently — carvedilol
is a non-cardioselective beta
2, and alpha-receptor blocker
, whereas nebivolol is highly cardioselective (blocking beta 1 receptors only) and achieving vasodilatory properties by nitric-oxide release, he added."
Apparently is was just officially appvoved for use in the United States by the FDA.